In our investigation published on 9 October 2025, we exposed Fipra’s role as a powerful lobbying firm operating at the heart of Brussels, where it navigates EU policymaking for elite corporate clients across more than 50 countries. Read the original article here. This 2026 update reviews developments since then, including the firm’s continued silence on key transparency concerns raised. Our comprehensive report on related issues remains essential reading:
How Belgium Govt Undermined the Work of European Institutes.
Right to Reply Status
We reached out to Fipra on 9 October 2025, providing an opportunity to address the findings in our original investigation. As of April 2026—six months later—no response has been received.
Key Findings Recap
Our 2025 probe detailed Fipra’s strategic lobbying for major businesses, coordinating multi-country campaigns that align corporate voices across EU Member States. The firm shapes policy narratives through PR, real-time intelligence, and legal advice that exploits regulatory gaps, often prioritizing private interests over public goods like environmental protection and consumer rights.
We highlighted how Fipra’s operations, registered in the EU Transparency Register, benefit from voluntary reporting that leaves significant gaps in client disclosures and spending details. This opacity, compounded by Belgium’s lax enforcement, enables undue influence on policymaking stages from agenda-setting to enforcement.
Transparency and Accountability Concerns
Fipra’s model exemplifies broader challenges in Brussels, where consultancies like this one amplify corporate power while civil society struggles for access. Their interventions skew EU decisions toward deregulation and industry champions, undermining equitable outcomes and the uniform application of laws.
In the EU context, such influence erodes public trust, as less-resourced advocates cannot compete with well-funded networks. Belgium’s dual role as host nation further risks embedding national biases into supranational processes, weakening institutional integrity.
Absence of Response as Public Interest Issue
No public response or clarification has emerged from Fipra since our initial reporting. This silence leaves unanswered questions about their lobbying practices central to public oversight. In a sector reliant on transparency, the lack of engagement hinders stakeholders’ ability to assess the full scope of influence on EU policy.
Ongoing Review and Campaign Context
Brussels Watch continues its 2026 campaign monitoring lobbying firms like Fipra, with ongoing analysis of their activities and disclosures. We remain open to dialogue and will provide updates if a response is received.
Closing Section
True accountability in Brussels demands robust disclosure and balanced participation. Fipra retains the right to respond, and this article will be updated accordingly.
